Research
Hormonal
PPARβ/δ activation reduces systemic inflammation and promotes fatty acid oxidation in skeletal muscle and brown adipose tissue, offering potential therapeutic benefits for obesity and insulin resistance.
PPARβ/δ activation shows promise for reducing inflammation and improving metabolism in muscle and fat, though it is still under clinical study.
ModerateSupportsMEDIUM confidence
This PPAR isoform is also expressed in adipocytes and macrophages, where it reduces the expression of proinflammatory markers... conferring the systemic anti-inflammatory activity of this isoform... PPAR-β/δ activators are under study for their clinical advantages in treating obesity.
Why this rating
Review of mechanistic studies.
Source
PPARs and Metabolic Disorders Associated with Challenged Adipose Tissue Plasticity
Patricia Corrales et al. · International Journal of Molecular Sciences · 2018
DOI 10.3390/ijms19072124
narrative_reviewCited 182×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Activation of PPARγ (via agonists like TZDs or endogenous upregulation) improves insulin resistance and metabolic homeostasis by enhancing adipose tissue expandability, reducing ectopic lipid accumulation, and promoting browning, rather than solely by reducing fat mass.Moderate
- PPARα activation promotes fatty acid oxidation and energy expenditure, particularly in the liver and brown adipose tissue, contributing to the treatment of hypertriglyceridemia and obesity-induced insulin resistance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →